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ABSTRACT
Dual antiplatelet therapy (DAPT) — a combination of a P2Y12 receptor inhibitor and aspirin 
— has revolutionized antithrombotic treatment. Potent P2Y12 inhibitors such as prasugrel 
and ticagrelor exhibit a strong and more consistent platelet inhibition when compared to 
clopidogrel. Therefore, ticagrelor and prasugrel significantly reduce ischemic events, but 
at an expense of an increased bleeding risk in acute coronary syndrome (ACS) patients 
undergoing percutaneous coronary intervention (PCI). These observations have engaged 
intensive clinical research in alternative DAPT regimens to achieve sufficient platelet 
inhibition with an acceptable bleeding risk. Our review focusses on P2Y12 receptor therapy 
de-escalation defined as a switch from a potent antiplatelet agent (ticagrelor or prasugrel) 
to clopidogrel. Recently, both unguided (platelet function testing independent) and guided 
(platelet function testing dependent) DAPT de-escalation strategies have been investigated 
in different clinical studies and both switching strategies could be possible options to 
prevent bleeding complications without increasing ischemic risk. In light of the still limited 
data currently available, future large-scale trials should accumulate more data on various 
DAPT de-escalation regimens with both ticagrelor and prasugrel in unguided and guided 
de-escalation approaches. In the current review we aim at summarizing and discussing the 
current evidence on this still emerging topic in the field of antiplatelet treatment.
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INTRODUCTION
Dual antiplatelet therapy (DAPT) — a combination of a P2Y12 receptor inhibitor and aspirin 
— has revolutionized antithrombotic treatment options in an acute coronary syndrome 
(ACS) patients with and without invasive management.1)2) The accessibility of a variety of P2Y12 
inhibitors enabled physicians to switch these drugs in reflection of individual patient features 
including their bleeding and thrombotic risk after stent implantation. The potent P2Y12 
inhibitors prasugrel and ticagrelor exhibit a strong and more consistent platelet inhibition 
when compared to clopidogrel. These pharmacologic properties resulted in a significant 
reduction in ischemic events, albeit at the expense of an increased bleeding risk in ACS 
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patients undergoing percutaneous coronary intervention (PCI).3-5) The challenge of preventing 
ischemic events with an acceptable bleeding risk of ACS patients by adapting P2Y12 receptor 
inhibitor therapy is a field of intensive research.2)6) Switching between oral P2Y12 inhibitors can 
either result in a stronger P2Y12 receptor inhibition (e.g. clopidogrel to prasugrel or ticagrelor) 
or reduced P2Y12 receptor inhibition (e.g. ticagrelor or prasugrel to clopidogrel). Those 
strategies are defined as DAPT escalation and de-escalation, respectively.7) In the pivotal phase 
III trials (PLATO, TRITON-TIMI 38) ticagrelor and prasugrel significantly reduced ischemic 
events especially in the early period after PCI when compared to clopidogrel.3)4)8) However, 
bleeding complications are an omnipresent issue during the entire maintenance phase of 
DAPT (Figure 1). In addition, switching to clopidogrel may have an economic advantage 
given the high treatment costs of ticagrelor and prasugrel.7) An unguided DAPT de-escalation 
approach is already adopted by many physicians when treating ACS patients after PCI9) but 
the limited data that is available is still conflicting.9)10) Moreover, the current clinical practice 
guidelines offer no clear recommendations on de-escalation of P2Y12 inhibitors, leaving 
clinicians uninformed on how to manage these patients.11)12) Our review summarizes and 
explains the rationale as well as the current evidence on de-escalating P2Y12 receptor inhibitor 
treatment, including both un-guided and guided treatment approaches.
GENERAL ASPECTS OF P2Y12 RECEPTOR THERAPY  
DE-ESCALATION
Oral P2Y12 receptor inhibitor treatment is a key element for secondary prevention 
of thrombotic events in ACS patients and especially for those patients with invasive 
management by means of PCI.2) For ACS patients the current clinical practice guidelines 
recommend a one-year treatment period with a potent P2Y12 inhibitors combined with 
aspirin.12-14) Prasugrel and ticagrelor are superior to clopidogrel in preventing ischemic 
events3)4) due to a more immediate and intense platelet inhibition. In general, escalated DAPT 
is accompanied by a higher risk for bleeding events and those bleeds are very prominent 
during the maintenance phase of treatment (Figure 1).3)4)15-18) Therefore, identification of 
appropriate patients for DAPT de-escalation may prove useful for an optimized and more 
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Figure 1. Timing of ischemic versus bleeding events after PCI. Ischemic and bleeding rates after PCI are displayed 
dependent on time. Whereas ischemic rates reach a plateau during the first month, bleeding rates steadily 
decline. In the second month, ischemic events substantially decrease resulting in an exuberant bleeding risk in 
the later phase post-PCI. 
PCI = percutaneous coronary intervention.
personalized P2Y12 receptor treatment after PCI. As outlined in Figure 2 there are factors that 
favor and there are factors against a DAPT de-escalation approach. In clinical practice, there 
is a variety of possibilities to downgrade the potency of antiplatelet treatment over time and 
this may include a dose reduction of potent P2Y12 receptor blockers,19) a discontinuation of 
aspirin12)20) and a possible shortening of the DAPT duration. Our review focuses on a true 
DAPT de-escalation defined as a switch from a potent P2Y12 blocker such as prasugrel or 
ticagrelor to clopidogrel.7) Indeed, many physicians already shorten the treatment duration 
with the potent drugs to the early weeks or months after the ACS event.9)21-23) The main 
reasons for de-escalation in this setting are reduced costs and concerns of bleeding during 
prasugrel and ticagrelor treatment, respectively. In case of ticagrelor, side effects such as 
dyspnea represent an additional possibility for modifying the ongoing treatment.3)24-26) 
Although there is general paucity of randomized data on de-escalating P2Y12 blocker therapy 
(Table 1), 2 randomized controlled trials have provided first and promising results on the 
efficacy and safety of such a biologically plausible treatment regimen. Whereas the timing 
of optimal platelet inhibition after acute coronary syndrome (TOPIC)27) trial investigated an 
unguided DAPT strategy that included both ticagrelor and prasugrel, Testing Responsiveness 
to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndrome 
(TROPICAL-ACS)28)29) used platelet function testing to guide DAPT de-escalation from the 
potent P2Y12 inhibitor prasugrel to clopidogrel.
UNGUIDED DUAL ANTIPLATELET THERAPY  
DE-ESCALATION
Observational data suggests an in-hospital de-escalation rate of 5–14% and a post-hospital 
switching rate of 5–8%.30) For instance, Treatment With Adenosine Diphosphate (ADP) 
Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute 
Coronary Syndrome (TRANSLATE ACS), a large multicenter, longitudinal registry in 12,365 
ACS patients captured data on post discharge switching in patients with acute myocardial 
infarction.30) Among patients discharged on prasugrel or ticagrelor a switch to clopidogrel 
was very common and strongly associated with having a government medication insurance 
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De-escalation
· Prior major bleeding
· Anemia
· Clinical significant bleeding
· Socioeconomic factors (insurance,
  financial hardship of current medication)
· Need for oral anticoagulation
· Side effects of Potent P2Y12 inhibitors
  (e.g. dyspnea in ticagrelor)
· Presumed high bleeding risk
+
· Prior stent thrombosis on adequate
  antiplatelet therapy
· Stenting of the last remaining patent
  coronary artery
· ≥3 stents implanted
· Bifurcation with two stents implanted
· Total stent length >60 mm
· Treatment of chronic total occlusion
−
Figure 2. The Pros and Cons of DAPT de-escalation. Characteristics marked in red are variables that may favor 
a DAPT de-escalation approach and variables marked in blue could be considered as factors that argue against 
DAPT de-escalation as an alternative DAPT strategy after PCI. Part of the figure content and variables are adapted 
from the ESC 2017 DAPT guidelines12). 
DAPT = dual antiplatelet therapy, PCI = percutaneous coronary intervention.
and financial hardship of medication costs. Bleeding events and increase in creatinine 
clearance were also associated factors prior to the switching. By contrast, a higher education 
was correlated with continuation of P2Y12 inhibitors suggesting costs as a main driver of 
switching. Switching after discharge from prasugrel or ticagrelor to clopidogrel was not 
associated with a significant increase in thrombotic events and GUSTO moderate/severe 
bleeding. Comparable results are derived from randomized data of the Comparison of 
Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction (PRAGUE-18) trial, 
which compared ticagrelor versus prasugrel in 1,280 ST-elevation myocardial infarction or 
high-risk non-ST-elevation myocardial infarction patients. After 12 months no significant 
differences in the composite endpoint (death, cardiovascular death, myocardial infarction, 
stent thrombosis, stroke and bleeding) were seen for ticagrelor and prasugrel in the intention 
to treat analysis (5.7% vs. 6.6%; p=0.50).31) Approximately half of the patients were switched 
and de-escalated to clopidogrel at the 12-month follow-up. Interestingly, most of the switches 
were due to economic reasons and 70% of them occurred early and during the 30-day period 
after the index event. In the PRAGUE-18 trial, an economically driven de-escalation to 
clopidogrel was associated with a reduction in thrombotic and bleeding events, whereas a 
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Table 1. Studies on P2Y12 receptor inhibitor de-escalation
Study  
(acronym) Approach
P2Y12 receptor 
inhibitors
No. of patients  
and study design Key results Ref.
TROPICAL-ACS Effect of PFT-guided 
de-escalation in 
PCI-treated patients
Prasugrel 2,610 ACS patients Primary endpoint (control vs. PFT-guided de-escalation):  
Net clinical benefit of CV death, MI, stroke, BARC bleeding ≥2  
(9% vs. 7%; HR, 0.81; 95% CI, 0.62–1.06; p=0.0004)
28)29)42)
Clopidogrel RCT Subgroup analysis (escalation vs. de-escalation)
- CV death, MI, stroke (3% vs. 3%; p=0.0115)
-  BARC bleeding events ≥2  
(6% vs. 5%; HR, 0.82; 95% CI, 0.59–1.13; p=0.23)
TOPIC Effect of unguided 
de-escalation in 
PCI-treated patients
Ticagrelor 646 ACS patients Primary endpoint: (control vs. unguided de-escalation): CV death, 
urgent revascularization, stroke, BARC bleeding ≥2 (26.3% vs. 13.7%; 
HR, 0.48; 95% CI, 0.34–0.68; p<0.01)
27)33)
Prasugrel RCT
Clopidogrel
SCOPE Investigate the 
incidence of 
switching P2Y12 
blocker and its 
safety in ACS 
patients with PCI
Ticagrelor 1,363 ACS patients Primary endpoint: MACE (1.6%) and NACE (5.6%) 32)
Prasugrel Observational study Switching rate: cath lab (2.3%), discharge (3.3%), follow-up (5.2%)
Clopidogrel Subgroup analysis (escalation vs. de-escalation)
- Patients with escalation: no NACE occurred among patients 
receiving an escalation (escalation vs. de-escalation: OR, 25.2;  
95% CI, 1.4–242.9; p=0.02)
- Patients with de-escalation: NACE increased  
(OR, 5.3; CI, 2.1–18.2; p=0.04)
TRANSLATE ACS Investigation of 
post-discharge P2Y12 
receptor blocker 
switching
Ticagrelor 
Prasugrel
12,365  
MI patients
Primary endpoint: MACE, factors for ADP receptor inhibitor choice 9)30)
Clopidogrel Observational study Switching rate: overall 7.6%
Switch in P2Y12 inhibitor groups: ticagrelor (28.3%), prasugrel (15.4%), 
clopidogrel (3.6%)
Main reasons for switching: costs (40.3%), physicians decision (60.7%)
PRAGUE-18 Evaluate treatment 
of ticagrelor 
versus prasugrel in 
patients with STEMI 
undergoing PCI
Prasugrel 1,230  
MI patients
Primary endpoint (prasugrel vs. ticagrelor): CV death, MI, stroke, 
all-cause mortality, definite stent thrombosis (HR, 1.167; 95% CI, 
0.742–1.835; p=0.503), all bleeding (10.9% vs. 11.1%; p=0.999), TIMI 
major bleeding (6.6% vs. 5.7%, p=0.754)
10)31)
Ticagrelor RCT Switching rate: economic (39%), anticoagulation (3.2%), adverse 
events (4.5%), other 6.8%
Studies addressing issues of P2Y12 inhibitor switching are described by approach, study design and key results. TROPICAL ACS and TOPIC are randomized 
controlled trials, whereas SCOPE and TRANSLATE ACS are observational studies on outcomes after switching. PRAGUE-18 was not intended to address P2Y12 
switching. This post-hoc analysis analyzes DAPT switching one year after randomization.
ACS = acute coronary syndrome; ADP = adenosine diphosphate; BARC = bleeding academic research consortium; CABG = coronary artery bypass grafting; 
CI = confidence interval; CV = cardiovascular; HR = hazard ratio; MACE = major adverse cardiac events; MI = myocardial infarction; NACE = net adverse 
cerebrovascular events (combination of MACE and bleeding events); NNT = number needed to treat; PCI = percutaneous coronary intervention; PFT = platelet 
function testing; PRAGUE-18 = Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction; RCT = randomized controlled trial; 
SCOPE = Switching From Clopidogrel to New Oral Antiplatelet Agents During Percutaneous Coronary Intervention; TIMI = thrombolysis in myocardial infarction; 
TROPICAL-ACS = Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndrome.
non-economically switch was accompanied by a higher ischemic event rate. Overall, patients 
who de-escalated to clopidogrel due to economic reasons had reduced risk compared 
with those who continued on ticagrelor or prasugrel. However, it must be emphasized 
that PRAGUE-18 investigators reported those outcome measures in relation to switch of 
treatment, while the trial was not specifically designed to address those questions.10)
Non-randomized registry data from the Switching From Clopidogrel to New Oral 
Antiplatelet Agents During Percutaneous Coronary Intervention (SCOPE) registry in 1,363 
patients revealed that ischemic events were substantially increased in patients undergoing 
a de-escalation approach after PCI for ACS.32) Such findings should raise a note of caution 
to an unguided de-escalation approach, although randomized data from a smaller single-
center trial is promising. Indeed, the TOPIC trial evaluated the clinical benefit of an 
unguided DAPT de-escalation by switching from prasugrel or ticagrelor to clopidogrel one 
month after PCI for ACS (Figure 3). This smaller single-center study enrolled 646 patients 
and the primary end point — a net clinical benefit endpoint consisting of cardiovascular 
death, urgent revascularization, stroke and bleeding as defined by the Bleeding Academic 
Research Consortium (BARC) classification — occurred in 13.4% in the switched versus 
26.3% in the unswitched group (hazard ratio [HR], 0.48; 95% confidence interval 
[CI], 0.34–0.68; p<0.01). This net benefit favoring DAPT de-escalation was driven by a 
reduction in overall bleeding events but it must be emphasized that ischemic events like 
stent thrombosis or myocardial infarctions were not reported in a detailed manner at all. 
Interestingly, in a platelet function testing (PFT) sub-study of the TOPIC trial (TOPIC-VASP) 
de-escalated DAPT was superior regardless of initial platelet reactivity, but the benefit 
was greater in low on-treatment platelet reactivity patients.33) Considering all the available 
evidence on an unguided DAPT de-escalation approach it must be emphasized that the data 
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Figure 3. Trials and possible strategies for un-guided and guided DAPT de-escalation. The figure shows studies and strategies on DAPT de-escalation approaches 
for P2Y12 receptor therapy. (A) Guided de-escalation of DAPT investigated in the TROPICAL-ACS trial. Patients were enrolled if they had biomarker-positive acute 
coronary syndrome with successful PCI and randomly assign to a PFT-based DAPT de-escalation arm or uniform prasugrel treatment. (B) Unguided DAPT de-
escalation investigated in the TOPIC trial. Patients with ACS and undergoing coronary intervention, on aspirin and a potent P2Y12 blocker were randomly assigned 
to switch to aspirin and clopidogrel or continuation of their drug regimen with a potent P2Y12 inhibitor. 
ACS = acute coronary syndrome, DAPT = dual antiplatelet therapy, PFT = platelet function testing; TOPIC = timing of optimal platelet inhibition after acute 
coronary syndrome; TROPICAL-ACS = Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndrome.
available is conflicting and that further studies in larger cohorts of patients are urgently 
needed to lend more support to such an unguided approach of de-escalating DAPT (early or 
late) in ACS patients after PCI.
GUIDED DAPT DE-ESCALATION
The pro-drug clopidogrel is characterized by a significant response variability and a 
substantial proportion of patients exhibit a status of high on-treatment platelet reactivity 
(HPR). This and other circumstances triggered the development of ex-vivo PFT assays.34-37) 
Indeed, DAPT de-escalation from a potent P2Y12 inhibitor to the less potent clopidogrel 
should account for the large response variability of the latter34) and the consequential issue 
of HPR, which exists in a relevant number of ACS patients.35)38)39) HPR patients exhibit a 
higher risk for ischaemic events including myocardial infarction and stent thrombosis.35)38)39) 
Hence, PFT could serve to safeguard a DAPT de-escalation by identifying HPR patients on 
clopidogrel, as those patients may be exposed to a higher risk of thrombotic events due to 
insufficient P2Y12 inhibition and they should therefore continue with potent P2Y12 inhibitors. 
Taking all these relevant aspects into consideration, the objective of the randomized, multi-
center investigator-initiated TROPICAL-ACS trial (n=2,610 patients) was to investigate the 
safety and efficacy of a PFT-guided early de-escalation of antiplatelet treatment compared 
to standard prasugrel therapy in ACS patients undergoing PCI. The trial met its primary 
endpoint and demonstrated non-inferiority for a net clinical benefit endpoint in patients 
scheduled for PFT guided de-escalation vs. conventional prasugrel treatment.29) Importantly, 
the rates of ischemic events including CV death, MI or stroke were similar in the guided 
de-escalation study group vs. control group and a trend towards less bleeding during 
guided treatment was reported. Therefore, a strategy of guided DAPT de-escalation can be 
considered in selected ACS patients (NSTEMI and STEMI) as an alternative to 12 months 
treatment with ticagrelor or prasugrel. It must be acknowledged that such a guided de-
escalation strategy results in clopidogrel treatment in most but not in all patients, as some 
patients would have to be escalated back to prasugrel. The TROPICAL-ACS trial was powered 
for demonstrating non-inferiority for the primary endpoint (net clinical benefit) and was not 
powered for ischemic events alone. Thus, large-scale trials would be helpful to corroborate 
the safety of such a concept with respect to ischemic risk of ACS patients after treatment de-
escalation. For the time being and based on the reported results a selective use of a guided 
DAPT de-escalation strategy seems reasonable and this strategy may be a good alternative 
for DAPT in selected patients and especially for those who cannot go for 1-year potent 
platelet inhibition.
Elderly ACS patients have a unique risk profile for both ischemic and bleeding events. The 
ANTARCTIC trial (Adjust Antiplatelet Therapy in Elderly Patients Stented for an Acute 
Coronary Syndrome) aimed to assess the safety and efficacy of PFT in 877 ACS patients 
≥75 years.40) The study compared a reduced dose of prasugrel (5 mg/d, as recommended 
for elderly patients) vs. PFT-guided escalation (10 mg prasugrel) or de-escalation (75 mg 
clopidogrel) in the intervention arm. Study results were neutral, with similar ischemic 
and bleeding rates in both groups (28% vs. 28%; HR, 1.003; 95% CI, 0·78–1·29; p=0·98). 
When interpreting ANTARCTIC results it should be noted that superiority of low-dose 
prasugrel over standard clopidogrel treatment in terms of clinical outcomes has not been 
demonstrated, independent of whether or not PFT was included.41) A subgroup analysis 
of TROPICAL-ACS also addressed the impact of age on clinical outcomes after guided 
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de-escalation. In patients younger than 70 years the incidence of the primary endpoint 
(cardiovascular death, myocardial infarction, stroke, BARC bleeding) was significantly lower 
in the guided de-escalation versus the control group (5.9% vs. 8.3%; HR, 0.70; 95% CI, 0.51–
0.96; p=0.03; NNT=42) mainly driven by reduced bleeding events. In patients older than 70 
years the primary endpoint occurred more frequent but was indistinguishable between both 
groups (15.5% vs. 13.6%).42) Thus, the age-dependent results from TROPICAL-ACS confirmed 
ANTARCTIC study results and a possible benefit of PFT with individualized treatment may be 
confined to younger patients while effects are neutral in the elderly.
THE EAST-ASIAN PARADOX OF PLATELET INHIBITION
Specific considerations must be reflected for the large population of East Asian patients, who 
carry a different and very specific risk profile for both ischemic and bleeding complications 
when compared to the Caucasian population.43) Related to this, a different and specific 
genetic profile (higher prevalence for the CYP2C19*2 and *3 Loss-of-Function [LoF] alleles) 
is associated with a significantly higher rate of HPR in East Asian patients. Despite this 
difference and very surprisingly, East Asians do not show an elevated risk for thrombotic 
complications. In contrast, a significantly lower risk of ischemic events was described leading 
to a phenomenon further referred to as the ‘East Asian paradox.’ Thus, based on these 
specific clinical observations, a right-shifted therapeutic window of on-treatment P2Y12-
directed platelet reactivity with higher cut-offs for HPR may apply to East Asian patients 
in contrast to Caucasians and this may have an impact on drugs and drug dosing for those 
patients. Moreover, with respect to a lower body mass index reduced doses of prasugrel and 
ticagrelor may be a good choice for East Asian patients specifically.
CONCLUSION AND OUTLOOK
In conclusion and based on the results of the pivotal phase III trials3)4) a 12 months DAPT 
that includes prasugrel or ticagrelor for ACS patients after PCI is standard of care in 2018 and 
beyond.12-14) However, a DAPT de-escalation must be considered as an attractive alternative 
treatment concept and may be considered in specific clinical scenarios (bleeding events, 
high bleeding risk, socio-economic indications) as an alternative to DAPT with potent 
P2Y12 receptor inhibitors (Figures 1 and 2). Based upon the current evidence any DAPT 
de-escalation should be guided and an unguided de-escalation may carry a substantial risk 
for the patient. Alternative treatment regimens of single antiplatelet therapy after stopping 
aspirin early after PCI and with continued treatment with a potent P2Y12 receptor inhibitor 
(ticagrelor) are under clinical investigation in the GLOBAL LEADERS (ClinicalTrials.gov, 
NCT01813435) and TWILIGHT (ClinicalTrials.gov, NCT02270242) trials. Those trials may 
have the potential to reduce bleeding risk without influencing antithrombotic efficacy. In 
contrast to a PFT guided adjustment of antiplatelet therapy, the TAILOR PCI (ClinicalTrials.
gov, NCT01742117) and POPular Genetics trial (ClinicalTrials.gov, NCT01761786) use a 
genetic approach of individualized DAPT. As clopidogrel response is dependent on CYP2C19 
polymorphisms,44-47) these trials investigate the usefulness of selective genotyping (CYP2C19) 
during P2Y12 receptor inhibitor treatment. All the published and ongoing trials in concert are 
important as attempts to move forward and to pave the way for a contemporary concept of 
a more personalized P2Y12 receptor inhibitor therapy that includes both escalation and de-
escalation strategies for selected patients.
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